Eurofins Scientific SE
PAR:ERF
Intrinsic Value
Eurofins Scientific SE engages in the bio-analytical testing of food, environment, and pharmaceuticals products. [ Read More ]
The intrinsic value of one
ERF
stock under the Base Case scenario is
76.16
EUR.
Compared to the current market price of 57.28 EUR,
Eurofins Scientific SE
is
Undervalued by 25%.
Eurofins Scientific SE's market capitalization is 11B EUR.
ERF stock price is 57.28 EUR.
ERF stock price (57.28 EUR) is 25% less than its Intrinsic Value (76.16 EUR).
ERF stock price (57.28 EUR) is 41% less than its Relative Value (97.91 EUR). Open Relative Valuation
ERF's Altman Z-Score is equal to 2.51.
ERF has positive Net Income for the last twelve months.
ERF has positive three-year average ROIC (Return on Invested Capital): 11%. The company is efficient at using invested capital to generate operating income.
ERF's Revenue has dropped by 3% over the past 12 months.
ERF's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 7%.
ERF earns more than enough operating income (842m EUR) to safely cover interest payments on its debt (82m EUR).
ERF's ROIC (Return on Invested Capital) has decreased in the last 3 years from 11% to 7%.
ERF's ROE (Return on Equity) for the past 12 months is positive and is equal to 5%.
ERF's Revenue has been growing by 6% per year for the last 3 years.
ERF's Revenue is forecast to grow at a rate of 8% per year over the next 3 years.
ERF has positive three-year average ROE (Return on Equity): 14%. The company is efficient at transforming stockholders' equity into net income.
ERF has positive Operating Income for the last twelve months.
ERF's ROE (Return on Equity) has significantly decreased in the last 3 years from 15% to 5%.
ERF's short-term assets (3B EUR) exceed its short-term liabilties (2B EUR).
ERF has positive Gross Profit for the last twelve months.
ERF has positive Free Cash Flow for the last twelve months.
ERF has positive Net Debt. This means that the company has more debt (3B EUR) than cash and short-term investments (1B EUR).
ERF's long-term assets (11B EUR) exceed its long-term liabilties (6B EUR).
ERF's D/E (Debt to Equity) is very low and is equal to 0.66.
Valuation Backtest
Eurofins Scientific SE
Run backtest to discover the historical profit from buying and selling
ERF
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Eurofins Scientific SE
Balance Sheet Decomposition
Eurofins Scientific SE
| Current Assets | 3.1B |
| Cash & Short-Term Investments | 1.2B |
| Receivables | 1.5B |
| Other Current Assets | 346.4m |
| Non-Current Assets | 7.8B |
| Long-Term Investments | 83.6m |
| PP&E | 2.3B |
| Intangibles | 5.3B |
| Other Non-Current Assets | 93.8m |
| Current Liabilities | 2.1B |
| Accounts Payable | 600.2m |
| Accrued Liabilities | 59.2m |
| Other Current Liabilities | 1.5B |
| Non-Current Liabilities | 3.7B |
| Long-Term Debt | 3.3B |
| Other Non-Current Liabilities | 363.8m |
Earnings Waterfall
Eurofins Scientific SE
|
Revenue
|
6.5B
EUR
|
|
Cost of Revenue
|
-5.2B
EUR
|
|
Gross Profit
|
1.4B
EUR
|
|
Operating Expenses
|
-522m
EUR
|
|
Operating Income
|
841.7m
EUR
|
|
Other Expenses
|
-585.2m
EUR
|
|
Net Income
|
256.5m
EUR
|
Free Cash Flow Analysis
Eurofins Scientific SE
ERF Profitability Score
Profitability Due Diligence
Eurofins Scientific SE's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
Score
Eurofins Scientific SE's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
ERF Solvency Score
Solvency Due Diligence
Eurofins Scientific SE's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Score
Eurofins Scientific SE's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ERF Price Targets Summary
Eurofins Scientific SE
According to Wall Street analysts, the average 1-year price target for
ERF
is 62.35 EUR
with a low forecast of 48.48 EUR and a high forecast of 87.15 EUR.
Shareholder Return
ERF Price
Eurofins Scientific SE
| Average Annual Return | 20.67% |
| Standard Deviation of Annual Returns | 39.64% |
| Max Drawdown | -63% |
| Market Capitalization | 11B EUR |
| Shares Outstanding | 192 025 142 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Eurofins Scientific SE
Country
Industry
Market Cap
Dividend Yield
Description
Eurofins Scientific SE engages in the bio-analytical testing of food, environment, and pharmaceuticals products. The firm joins a part of international group of laboratories providing a range of analytical testing services to the pharmaceutical, food, environmental and consumer products industries and to governments. The company operates through a number of subsidiaries, such as VRL Laboratories in the United States, Institut Nehring GmbH in Germany, Agfirst Bay of Plenty, a fruit maturity testing laboratory in New Zealand, and Megalab SA, a clinical diagnostic laboratory in Spain.
Contact
IPO
Employees
Officers
The intrinsic value of one
ERF
stock under the Base Case scenario is
76.16
EUR.
Compared to the current market price of 57.28 EUR,
Eurofins Scientific SE
is
Undervalued by 25%.
You don't have any saved screeners yet
